COPENHAGEN, Denmark,
Sept. 13, 2017 /PRNewswire/ --
Veloxis Pharmaceuticals A/S (OMX: VELO) is pleased to announce
that Veloxis Pharmaceuticals, Inc. has hired Ulf Meier-Kriesche, MD, to serve as its Chief
Scientific Officer. In this role, Dr. Meier-Kriesche will oversee
the Company's regulatory and medical affairs departments.
Dr. Meier-Kriesche is a board certified Nephrologist with over
20 years of practical clinical experience in
transplantation. He is the author of over 170 scientific
publications that have appeared in numerous peer-reviewed journals.
Additionally, Dr. Meier-Kriesche served on the faculty of the
University of Florida Medical School
from 2001 until 2011.
Prior to joining Veloxis, Dr. Meier-Kriesche was the Clinical
Trials Lead Immunology at Bristol-Myers Squibb. Dr.
Meier-Kriesche has also worked for Astellas
Pharma.
Craig Collard, CEO of Veloxis
Pharmaceuticals A/S said, "Veloxis is committed to serving the
needs of the transplant community and the appointment of
Ulf Meier-Kriesche further
solidifies that commitment. Ulf's background and experience as
a transplant nephrologist will help Veloxis be more responsive to
the concerns of clinicians and ultimately better support the
transplant community."
Ulf Meier-Kriesche commented, "I
am thrilled to join Veloxis because of the wonderful opportunity we
have together to bring new therapeutic options to transplant
patients."
About Veloxis Pharmaceuticals
Veloxis Pharmaceuticals A/S is a commercial-stage specialty
pharmaceutical company committed to improving the lives of
transplant patients. A Danish company, Veloxis
Pharmaceuticals A/S operates in the U.S. through Veloxis
Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in
Cary, North Carolina, USA.
Veloxis has successfully developed Envarsus XR (tacrolimus
extended-release tablets) based upon the company's unique and
patented delivery technology, MeltDoseĀ®, which is designed to
enhance the absorption and bioavailability of select orally
administered drugs. The company is focused on the direct
commercialization of Envarsus XR in the U.S., expansion of
partnerships for markets around the world, and acquisition of
assets utilized in transplant patients and by adjacent medical
specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under
the trading symbol OMX: VELO. For further information, please
visit www.veloxis.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-inc-appoints-ulf-meier-kriesche-md-as-chief-scientific-officer-300519310.html
SOURCE Veloxis Pharmaceuticals